CymaBay Therapeutics Inc (NASDAQ:CBAY) FY22 R&D Increases
CymaBay Therapeutics Inc (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, stock rose 5.74% (As…
